Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yttrium-90 besilesomab - TheraPharm

Drug Profile

Yttrium-90 besilesomab - TheraPharm

Alternative Names: 90Y-anti-CD66-MTR; Y-90-anti-CD66; Yttrium-90 labelled anti-CD66 monoclonal antibody

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraPharm
  • Developer Great Ormond Street Hospital; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies
  • No development reported Leukaemia

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for phase-I development in Leukaemia(In adolescents, In children, In infants, In neonates, Second-line therapy or greater) in United Kingdom (IV, Infusion)
  • 29 Apr 2021 Great Ormond Street Hospital for Children NHS Foundation Trust plans a phase II trial for Leukaemia (In adolescents, In children) in June 2021 (Parenteral) (NCT04856215)
  • 30 Nov 2020 Yttrium-90 besilesomab receives Orphan Drug status for Haematological malignancies in European Union before November 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top